ADMA CEO reports tax share withholding on RSUs

ADMA Biologics President and CEO Adam S. Grossman reported a Form 4 transaction where 24,793 shares of common stock were withheld on February 19, 2026 at $16.32 per share to cover mandatory tax obligations upon the vesting of restricted stock units.

Rhea-AI Filing Summary

ADMA Biologics President and CEO Adam S. Grossman reported a Form 4 transaction where 24,793 shares of common stock were withheld on February 19, 2026 at $16.32 per share to cover mandatory tax obligations upon the vesting of restricted stock units. Footnotes clarify this was a tax-withholding disposition and not an open market sale.

After this transaction, Grossman directly owned 2,259,586 shares of ADMA common stock. He also had indirect ownership of additional shares, including positions held through Areth, LLC and Hariden, LLC, where he is a control person and managing member, respectively.

Insider Trade Summary

Exercise Price or Tax Liability: 24,793 shares

Exercise Price or Tax Liability 3 txns

Insider Grossman Adam S

Role President and CEO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	24,793	$16.32	$405K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,259,586 shares (Direct); Common Stock — 1,724,383 shares (Indirect, See Footnote)

Footnotes (6)

1. F1. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.
2. F2. Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
3. F3. (continued from footnote 2) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
4. F4. (continued from footnote 3) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 1,007,896 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
5. F5. These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.
6. F6. These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ADMA (ADMA) CEO Adam Grossman report in this Form 4?

Adam S. Grossman reported a tax-withholding disposition of ADMA common stock. 24,793 shares were withheld on February 19, 2026 to cover mandatory taxes owed upon RSU vesting, rather than being sold in the open market.

How many ADMA shares were involved in the CEOs tax-withholding transaction?

The Form 4 shows 24,793 ADMA common shares were withheld at $16.32 per share. These shares satisfied the CEOs tax obligations when restricted stock units vested, and did not represent a discretionary market sale of stock.

Was the ADMA CEOs Form 4 transaction an open market stock sale?

No, footnotes specify it was not an open market sale. The 24,793 shares were withheld by ADMA Biologics solely to meet mandatory tax withholding requirements tied to vesting restricted stock units, a common administrative equity process.

How many ADMA shares does CEO Adam Grossman own after this Form 4?

Following the tax-withholding transaction, Adam Grossman directly held 2,259,586 ADMA common shares. The filing also reports additional indirect holdings through entities such as Areth, LLC and Hariden, LLC, where he exercises control or management roles.

What indirect ADMA shareholdings are associated with the CEO in this filing?

The Form 4 lists indirect ownership of ADMA shares through Areth, LLC and Hariden, LLC. Footnotes state the CEO is a control person of Areth and the managing member of Hariden, linking these holdings to him as indirect beneficial ownership.

How does this ADMA Form 4 describe the CEOs restricted stock units (RSUs)?

Footnotes detail multiple grants of unvested RSUs that vest quarterly over four years, subject to continued service. Upon vesting, these RSUs are settled in common stock, and prior vestings have used net share settlement after tax withholding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 09:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grossman Adam S

(Last) (First) (Middle)

C/O ADMA BIOLOGICS, INC.

465 STATE ROUTE 17

(Street)

RAMSEY NJ 07446

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		F		24,793(1)	D	$16.32	2,259,586(2)(3)(4)	D
Common Stock								1,143,426	I	See Footnote(5)
Common Stock								580,957	I	See Footnote(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

2. Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

3. (continued from footnote 2) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

4. (continued from footnote 3) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 1,007,896 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

5. These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.

6. These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.

	/s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.